REDUCE study Discloses that Dutasteride decreases risk of biopsy Detectable Prostate Cancer by 22.8%

January 22, 2013 by  
Filed under Prostate Cancer News

REDUCE stands for REduction by DUtasteride of prostate cancer Events). It is a four-year clinical study on the effect of the use of Dutasteride [a 5-alpha-reductase inhibitor (5ARI)].

Results from the study that were recently published in The Journal of Urology have indicated that the use of dutasteride decreased the risk of biopsy detectable prostate cancer by 22.8 %.

These details were published online in a post made in the News Medical website on January 22, 2013. The following are highlights of the online publications:

The four-year REDUCE (REduction by DUtasteride of prostate Cancer Events) clinical study evaluated prostate cancer risk reduction in men taking dutasteride, a 5-alpha-reductase inhibitor (5ARI) typically used to treat enlarged prostate. REDUCE results showed that dutasteride decreased the risk of biopsy detectable prostate cancer by 22.8 percent compared to a placebo group, but concerns remained about the drug’s effectiveness. Results from a follow-up study are now published in The Journal of Urology®.

Dutasteride (credit:google image)

“The REDUCE Follow-up Study was a two-year observational follow-up of men who participated in the four-year REDUCE trial,” says lead investigator Robert L. Grubb III, Associate Professor of Surgery (Urology), Washington University of Medicine in St. Louis, Missouri. “The primary objective was to collect data on the occurrence of new cases of prostate cancer for two years beyond REDUCE.”

Nearly 2,800 men from the REDUCE study participated, representing extension safety and at-risk populations. In the original study, about half were treated with dutasteride and the remainder received a placebo.

Shortly after the REDUCE study’s conclusion, Dr. Grubb and co-investigators followed participants with a clinic visit. They also conducted up to two annual telephone calls, collecting patient data on prostate cancer events, chronic medication use, prostate specific antigen levels, and serious adverse events. No drugs were administered and no additional biopsies were performed except those “for-cause” when clinically indicated.

Results showed that few new prostate cancers were detected during the two-year follow-up in either treatment group and no deaths were reported. However, the former dutasteride group produced double the number of cancers than the former placebo group (14 vs. 7). Investigators hypothesize that any prostate cancer that may have been suppressed by dutasteride during REDUCE was no longer being suppressed for those subjects who did not continue on 5ARI therapy. To some extent, observations during the follow-up study support this concept.

Click here to read more on the study

Conclusively, from the excerpt above, it becomes really important to know that the risk of biopsy detectable prostate cancer has been reduced quite significantly with the use of dutasteride.

The study researchers still highlight the facts that there are still limitations to the four year study.

These limitations have been pinpointed in the penultimate paragraph of the extract. You can read The Journal of Urology for more details on this study.

Below Are Other Related Articles Among 1,000+ Prostate Cancer Articles On
This HUGE 4+ Year Old Prostate Cancer Victory Authority Website:

(95% of these 1,000+ Prostate Cancer Articles on this website
are written by our Expert In -house Writers, after lots of research.
The remaining 5% are news articles and videos from relevant sources!)

  1. Surgery Does Not Reduce All-Cause Mortality among Men with Localized Prostate Cancer – Study
  2. BPH Drug May Delay Progression of Prostate Cancer – Study
  3. Study Shows Aspirin Intake in Men with Prostate Cancer Helped to Reduce Their Mortality
  4. An African Herb, Sutherlandia (Cancer Bush) May Reduce the Risk of Prostate Cancer
  5. Drinking Coffee Lowers the Risk of Prostate Cancer – A Harvard Study
  6. Magnetic Resonance Ultrasound Fusion Targeted Biopsy Detects Prostate Cancer Better – Study
  7. Vitamin E Increases Prostate Cancer Risk? New Study Thinks So.
  8. Fizzy Drinks Increase Risk of Aggressive Prostate Cancer in Men – Study
  9. Multivitamins Intake May Lower the Risk of Prostate Cancer – A New Study
  10. Men with High Skeletal Risk Are Likely to Have More Fractures After Hormonal Treatment For Prostate Cancer – New Study
  11. Night Shift Increases The Risk of Prostate Cancer – Study
  12. Soft drink Increases the Risk of Aggressive Prostate Cancer – A New Swedish Study
  13. How Red Meat is Cooked and How it is Consumed Increase The Risk Of Prostate Cancer – A New Study
  14. Breast Cancer Drug — Tamoxifen — Can Reduce the Side effects of Prostate Cancer Treatments
  15. Biopsy for Prostate Cancer – Important Points to Note

Speak Your Mind

Tell us what you're thinking... !